



To the Editor: I have read with interest the study by
Srivastava et al.1 reporting no difference in peritonitis rates
and technique survival in patients randomized to biocompa-
tible or conventional peritoneal dialysis (PD) solutions.
However, PD-related peritonitis is not the only cause of PD
technique dropout, and the data provided do not fully clarify
whether the PD technique survival rates in ﬁgures 1 and 2 were
calculated only with regard to dropouts due to resistant-to-
therapy PD peritonitis, or whether other reasons such as PD
catheter malfunction, leaking, etc., were also included.
The study also reports a rather high rate of culture-negative
peritonitis episodes (23.7%) that exceeds the suggested upper
threshold of the International Society for Peritoneal Dialysis
recommendations.2
It is also well established that not all PD-related peritonitis
episodes are of equal clinical signiﬁcance. With regard to Gram-
positive microorganisms, coagulase-negative Staphylococci have
usually a more favorable outcome, whereas Staphylococcus
aureus or Enterococcus species may lead to resistant-to-therapy
peritonitis and a need for PD catheter removal. The same may
also apply for Gram-negative microorganisms such as Pseudo-
monas species and deﬁnitely for fungal peritonitis.2 It is
noteworthy that there were three cases of fungal peritonitis in
the conventional PD solutions group but only one in the
biocompatible group. Thus, an analysis of the exact incidence of
dropouts due to peritonitis only is warranted before reaching
the deﬁnite conclusion that there is no clinical difference
regarding peritonitis between these solutions.
1. Srivastava S, Hildebrand S, Fan SLS. Long-term follow-up of patients
randomized to biocompatible or conventional peritoneal dialysis solutions
show no difference in peritonitis or technique survival. Kidney Int 2011; 80:
986–991.
2. Piraino B, Bailie GR, Bernardini J et al. Peritoneal dialysis-related infections
recommendations: 2005 update. Perit Dial Int 2005; 25: 107–131.
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The Authors Reply: Prof. Fourtounas1 raised some pertinent
issues about the importance of selecting appropriate end points
for a study that compares ‘biocompatible’ peritoneal dialysis
(PD) solutions against their ‘standard’ counterpart.
We did not compare PD technique survival between the
two groups with the outcome censored for all ‘noninfective’
causes of change of modality.2 It is true that modality changes
caused by PD catheter malfunction and leaks are unlikely to
be related to the type of PD solution. Thus, our choice of end
point is associated with increased ‘noise’ and reduced the
chance that a statistically signiﬁcant outcome related to the
use of biocompatible PD solution would be found. Never-
theless, we believe that our primary end points were the most
clinically relevant. Moreover, it is our policy to continually
perform risk assessments on PD patients, and frequent peritonitis
may have precipitated an elective switch to hemodialysis. If
the primary end point only included patients with PD peritonitis
resistant to treatment, we would not include these ‘elective
switch’ patients. We must also remember that our study was
not and could not be blinded, and thus hard end points were
essential. For these reasons, we deﬁned PD technique failure
as any cause of transfer to hemodialysis (censored for
transplantation, transfer out of unit þ / death).
Should we have performed a sub-analysis examining the
peritonitis rate caused by ‘virulent’ organisms (Staphylococcus
aureus, Enterococci, Gram-negative bacteria, including Pseu-
domonas, and fungi)? In fact, I would suggest that the beneﬁt
of improved neutrophil function is most likely to be demon-
strated by reduced infections from low virulent bacteria; i.e., it
would not have been logical to have prespeciﬁed infection
rates from ‘virulent’ organisms as a primary end point.
Pre-specifying peritonitis caused by speciﬁc organisms as
an end point for our study would have reduced the power of
the study. Our ‘virulent’ organism peritonitis rate was 0.118
episodes per patient-year. Even with over 250 patient-years of
follow-up in each group, our study would only be powered to
detect a 450% reduction in infection rate (type I error 0.05,
type II error 80%)—we would not realistically expect such a
marked reduction of infections from Pseudomonas, Candida,
etc., through the use of biocompatible PD solutions.
By noting a small (nonsigniﬁcant) difference in fungal
peritonitis rate and going on to compare the infection rate
caused by ‘high virulent’ organism is to risk the accusation of
‘data trawling’. Nevertheless, we have looked at our data as
Table 1 | Peritonitis rate of patient treated with biocompatible vs. standard peritoneal dialysis (PD) solutions with particular
emphasis on ‘virulent’ pathogens














Standard 3465 110.00 5 (0.017) 22 (0.076) 3 (0.010) 4 (0.014) 34 (0.118)
Biocompatible 3943 117.00 2 (0.061) 19 (0.058) 7 (0.021) 2 (0.061) 30 (0.091)
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suggested by Prof. Fourtonunas. The number and the cause of
infections are shown in Table 1. Sufﬁce to say that there were
no statistical differences in peritonitis rates caused by
‘virulent’ organisms, although the lack of power of such an
analysis needs to be reiterated.
We thank Prof. Fourtounas for his interest in our study
and the discussion that has ensued from his pertinent
observations.
1. Fourtounas C. Peritonitis rates with biocompatible and conventional
peritoneal dialysis solutions. Kidney Int 2012; 81: 1150.
2. Srivastava S, Hildebrand S, Fan SLS. Long-term follow-up of patients
randomized to biocompatible or conventional peritoneal dialysis solutions
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Chronic kidney disease in
Pakistan: an under-recognized
public health problem
To the Editor: We read with interest Couser et al.’s1 article,
which highlighted the global burden of chronic kidney disease
(CKD) and its inequitable distribution among developing
countries. In a survey conducted in 2011 in Karachi, a city
harboring 9% of Pakistan’s population, where we looked at
serum creatinine of 300 adults 30 years or older from the
community, an astonishing 25.3% had some degree of
reduced glomerular ﬁltration rate (GFR), with 5% having
moderate CKD (GFR o60ml/min).2 Even more disturbing
was the fact that only 2.3% individuals were aware of having
renal disease, most people with lower income falling in to this
category. In this subset, 20% had coexistent diabetes, 65% had
HTN, and 10% had both conditions. Extrapolation of these
ﬁndings translates to 12.86 million Pakistanis above 30 years
of age having some degree of renal impairment, which is
representative of a huge disease burden.
With rampant lack of awareness in developing countries,
there is underdetection of earlier stages of CKD, leading to
lack of preventive measures, which inevitably facilitates
progression of mild, potentially treatable CKD to full-blown
kidney failure. Where the annual cost of dialysis of a single
patient is over $3000, annual per capita income is $1200, and
spending on health is a meager 0.23% of the gross national
product, it is not surprising that although the incidence of
end-stage renal disease is estimated to be between 34 and 240
per million people, only 10% receive any renal replacement
therapy.3 The dire need of international programs aimed at
preventing and controlling CKD in third-world countries
such as Pakistan cannot be stressed on enough.
1. Couser WG, Remuzzi G, Mendis S et al. The contribution of chronic kidney
disease to the global burden of major noncommunicable diseases. Kidney
Int 2011; 80: 1258–1270.
2. Jafri AKS, Patel JW, Qidwai W et al. Point prevalence of CKD in the general
population in an urban city of Pakistan. 2011 (in press).
3. Jafar TH SC, Levey AS. Serum creatinine as marker of kidney function in
South Asians: a study of reduced GFR in adults in Pakistan. J Am Soc
Nephrol 2005; 16: 1413–1419.
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The Authors Reply: We thank Drs Saeed and Hussain1 for
providing these interesting data about chronic kidney disease
(CKD) in Karachi, Pakistan, and conﬁrming again the high
burden and very low awareness of CKD in an urban devel-
oping country setting. We hope our paper, which prompted
the letter,2 and additional information like this from Pakistan
and other countries, will contribute to expanding awareness
of CKD as a major global health problem.
We agree completely with Dr Saeed that ‘international
programs aimed at prevention and control of CKD in third-
world countries’ are indeed badly needed and represent the
only economically feasible approach to the long-term reduc-
tion of CKD and its consequences, including both cardiovas-
cular disease and end-stage renal disease. We are encouraged
that the political declaration of the recent High-Level Meeting
of the United Nations General Assembly on the Prevention
and Control of Non-Communicable Diseases identiﬁed renal
diseases for the ﬁrst time as posing a major health burden for
many countries and acknowledged that these diseases share
common risk factors with other non-communicable diseases
and can beneﬁt from common responses.3 We hope our
efforts and those of the International Society of Nephrology4
have contributed to ﬁnally getting kidney disease a place on
the global health agenda. We call on all of our colleagues in
the international renal community to continue efforts such as
those of Drs Saeed and Hussain to document and increase
awareness of CKD and to translate these advances to tangible
changes in public health policy that will beneﬁt all kidney
patients in the future.
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